Elevation of urinary 2-hydroxyglutarate in IDH-Mutant Glioma

Oncologist

Volumn 21, Issue 2, 2016, Pages 214-219

  Fathi, Amir T ^a   Nahed, Brian V ^a   Wander, Seth A ^a   Iafrate, A John ^a   Borger, Darrell R ^a   Hu, Ranliang ^a   Thabet, Ashraf ^a   Cahill, Daniel P ^a   Perry, Ashley M ^a   Joseph, Christelle P ^a   Muzikansky, Alona ^a   Chi, Andrew S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

2 Hydroxyglutarate; Glioma; Isocitrate dehydrogenase; Novel biomarkers; Targeted therapies

Indexed keywords

2 HYDROXYGLUTARIC ACID; CREATININE; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER GRADING; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; URINALYSIS; URINE LEVEL; BLOOD; GENETICS; GENOTYPE; MUTATION; PATHOLOGY; URINE;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GENOTYPE; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION;

EID: 84957593126     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0342     Document Type: Article

References (39)

1. Parsons DW, Jones S, Zhang X et al. Anintegrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–1812.
2. Lai A, Kharbanda S, Pope WB et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482–4490.
3. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations ingliomas. N Engl JMed 2009;360:765–773.
4. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4154.
5. Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathol 2010; 120:707–718.
6. Watanabe T, Nobusawa S, Kleihues P et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149–1153.
7. Johnson BE, Mazor T, Hong C et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189–193.
8. Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1andIDH2mutations are relatedto astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469–474.
9. Bettegowda C, Agrawal N, Jiao Y et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011;333:1453–1455.
10. Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324: 261–265.
11. Bleeker FE, Lamba S, Leenstra S et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009;30:7–11.
12. Gross S, Cairns RA, Minden MD et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2mutations. J Exp Med 2010; 207:339–344.
13. Dang L, White DW, Gross S et al. Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–744.
14. Chowdhury R, Yeoh KK, Tian YM et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12:463–469.
15. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.
16. Koivunen P, Lee S, Duncan CG et al. Transformationbythe(R)-enantiomerof2-hydroxyglutarate linked to EGLN activation. Nature 2012;483:484–488.
17. Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474–478.
18. Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17–30.
19. Losman JA, Looper RE, Koivunen P et al. (R)-2- Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339:1621–1625.
20. Saha SK, Parachoniak CA, Ghanta KS et al. Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. Nature 2014;513:110–114.
21. Sasaki M, Knobbe CB, Munger JC et al. IDH1 (R132H)mutation increasesmurinehaematopoietic progenitors and alters epigenetics. Nature 2012; 488:656–659.
22. Turcan S, Rohle D, Goenka A et al. IDH1mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479–483.
23. Fathi AT, Sadrzadeh H, Borger DR et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acutemyeloid leukemia, to assess disease activity and therapeutic response. Blood 2012;120:4649–4652.
24. Borger DR, Goyal L, Yau T et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 2014;20:1884–1890.
25. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225–234.
26. Fathi AT, Sadrzadeh H, Comander AH et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. The Oncologist 2014;19:602–607.
27. Capper D, Simon M, Langhans CD et al; German Glioma Network. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlatewith IDH1/2 mutation status or tumorsize. Int J Cancer 2012;131:766–768.
28. Lombardi G, Corona G, Bellu L et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenasemutated glioma. The Oncologist 2015;20:562–567.
29. Mohapatra G, Betensky RA, Miller ER et al. Glioma test array for use with formalin-fixed, paraffin-embedded tissue: Array comparative genomic hybridization correlates with loss of heterozygosityand fluorescence in situ hybridization. J Mol Diagn 2006;8:268–276.
30. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO MolMed 2010;2:146–158.
31. Capper D, Weissert S, Balss J et al. CharacterizationofR132Hmutation- specific IDH1antibody binding in brain tumors. Brain Pathol 2010;20:245–254.
32. Killela PJ, Reitman ZJ, Jiao Y et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of selfrenewal. Proc Natl Acad Sci USA 2013;110:6021–6026.
33. Jiao Y, Killela PJ, Reitman ZJ et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709–722.
34. Killela PJ, Pirozzi CJ, Healy P et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014;5:1515–1525.
35. Luchman HA, Stechishin OD, Dang NH et al. An in vivo patient-derived model of endogenous IDH1- mutant glioma. Neuro-oncol 2012;14:184–191.
36. Nakamizo S, Sasayama T, Shinohara M et al. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neurooncol 2013;113:65–74.
37. Andronesi OC, Rapalino O, Gerstner E et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013;123:3659–3663.
38. Andronesi OC, Kim GS, Gerstner E et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4.
39. Beiko J, Suki D, Hess KR et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neurooncol 2014;16:81–91.